New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:43 EDTENZY, ACST, NEPTNeptune, Acasti say patent settlement with Enzymotec not finalized
Neptune Technologies (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec (ENZY) that would resolve the International Trade Commission investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. the Administrative Law Judge presiding over the pending ITC Investigation previously stay the proceedings through February 5 to give the parties more time to finalize a settlement agreement. To date, the parties have reached an impasse on certain fundamental settlement terms, including terms to which Enzymotec had already agreed in the parties' signed term sheet. Consequently, as strongly encouraged by the ITC, Neptune will participate in the ITC's Mediation Program in a final attempt to reach a mutually satisfactory agreement. The mediation process is expected to be completed over the next 45 to 60 days.
News For NEPT;ACST;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:37 EDTACSTAcasti Pharma granted patent in China
Subscribe for More Information
March 23, 2015
19:10 EDTACST, NEPTNeptune, Acasti announce USPTO decision that triggers royalty payments
Neptune Technologies & Bioressources (NEPT) and Acasti Pharma (ACST) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, or USPTO, issued a favorable decision, confirming the validity of certain claims in Neptune's '351 patent and triggering royalty payments to Neptune. "This is a significant milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US," said Neptuine CEO Jim Hamilton.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use